{"entity":{"id":"sofetabart-mipitecan","kind":"drug","name":"Sofetabart Mipitecan","aka":["Sofe-M"],"tldr":"Sofetabart Mipitecan is an experimental antibody-drug conjugate from Eli Lilly and in phase 3 trials for ovarian cancer, aimed at Folate receptor alpha.","summary":"Sofetabart Mipitecan (LY4170156) is an antibody-drug conjugate developed by Eli Lilly and. Its target is Folate receptor alpha (the sponsor names folate receptor alpha). The sponsor states: An antibody-drug conjugate targeting folate receptor alpha that delivers a topoisomerase inhibitor payload to cancer cells. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07213804 (A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer), in ovarian cancer. The largest, NCT07213804, plans to enrol 1630 participants with primary completion expected 2028-11. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Sofetabart Mipitecan","url":"https://clinicaltrials.gov/search?intr=LY4170156"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":["folr1"],"drugs":[],"companies":["eli-lilly"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07213804"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"LY4170156","modality":"ADC","mechanism":"An antibody-drug conjugate targeting folate receptor alpha that delivers a topoisomerase inhibitor payload to cancer cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/sofetabart-mipitecan/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"target":[{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"}],"trial":[{"id":"nct07213804","kind":"trial","name":"A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer","route":"/trials/nct07213804/"}]}}